October 2024
Enanta Pharmaceuticals Achieves Breakthrough in RSV Treatment with EDP-323, Demonstrating Significant Reductions in Viral Load and Symptoms
Enanta Pharmaceuticals, EDP-323, Respiratory Syncytial Virus (RSV), Antiviral Treatment, Phase 2a Human Challenge Study, Viral Load Reduction, Symptom Alleviation
Rivus Pharmaceuticals Unveils Promising Phase 2a Results for HU6 in Obesity-Related Heart Failure Patients
HU6, Rivus Pharmaceuticals, obesity-related heart failure, fat-selective weight loss, controlled metabolic accelerators (CMAs), mitochondrial uncoupling, cardiometabolic diseases.
UK Regulator Approves Pharming’s Joenja for Rare Immune Disorder APDS, Leveraging FDA Review
Joenja, leniolisib, APDS, MHRA approval, FDA review, rare immune disorder, Pharming
Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants
Aktis Oncology, Series B funding, targeted alpha radiopharmaceuticals, cancer treatment, pharmaceutical industry, investment, Lilly, BMY, MRK.
Roche Invests $850 Million in Regor’s Next-Generation CDK Inhibitors for Breast Cancer Treatment
Roche, Regor Pharmaceuticals, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition